Bicara Therapeutics Inc. Common Stock

BCAXNASDAQHealthcare● Active

$20.01

+$0.01(+0.05%)

Market Cap$1.1B

P/E Ratio—

52W High$24.25

52W Low$8.48

Avg Volume557K

Open$20.55

Beta-0.53

Overview

Bicara Therapeutics Inc. Common Stock（BCAX）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

bcax · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 7 位华尔街分析师

Buy

7 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 7 · 买入占比: 71.4%

12 个月目标价

High

$42.00

Consensus

$28.60

+42.6% upside

Low

$18.00

Median: $28 · Last Close: $20.05

Bicara Therapeutics Inc. Common Stock（BCAX）的分析师共识为 Buy，基于过去 3 个月内 7 位华尔街分析师的评级。BCAX 的 12 个月平均目标价为 $28.60，相对当前价 $20.05 代表 +42.6% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $29 (42.6%)High $42Low $18

Consensus Target

$28.60

42.6% upside

High Target

$42

109.4%

Low Target

$18

-10.2%

Current Price

$20.05

as of today

Based on analyst price targets, the BCAX stock price prediction for the next 12 months ranges from $18 to $42. The consensus BCAX price forecast of $28.60 implies 42.6% upside from the current price of $20.05.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$19.48	↓ 2.89%	$19.37	$19.58

1-day model range: $19.37–$19.58. Peak: $19.58 (-2.89%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$43	$44	$45	+120.0%
2028	$70	$73	$76	+265.2%
2029	$95	$100	$105	+397.8%
2030	$113	$120	$127	+497.1%
2031	$124	—	$142	+562.7%

Confidence:MediumCapped at 120% annual limit

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

36%7%57%

5Buy

1Neutral

8Sell

RSI (14)55.8Neutral

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · BCAX · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$20.02BUY

MA 10$20.78SELL

MA 20$20.86SELL

MA 50$21.60SELL

MA 100$19.37BUY

MA 200$17.48BUY

Current $BCAX · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$20.22SELL

EMA 10$20.50SELL

EMA 20$20.88SELL

EMA 50$20.84SELL

EMA 100$19.74BUY

EMA 200$17.41BUY

Current $BCAX · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2026-05-12	Morgan Stanley	Maintains	Overweight→Overweight
2026-05-12	Goldman Sachs	Maintains	Neutral→Neutral
2026-03-31	Wedbush	Maintains	Outperform→Outperform
2026-03-31	Citizens	Maintains	Market Outperform→Market Outperform
2026-03-31	HC Wainwright & Co.	Maintains	Buy→Buy
2026-03-31	Goldman Sachs	Maintains	Neutral→Neutral
2026-03-31	Wells Fargo	Maintains	Equal Weight→Equal Weight
2026-01-13	Wedbush	Maintains	Outperform→Outperform
2025-11-11	Wells Fargo	Maintains	Equal Weight→Equal Weight
2025-08-22	HC Wainwright & Co.	Maintains	Buy→Buy

Morgan Stanley2026-05-12

Maintains

Overweight→Overweight

Goldman Sachs2026-05-12

Maintains

Neutral→Neutral

Wedbush2026-03-31

Maintains

Outperform→Outperform

Citizens2026-03-31

Maintains

Market Outperform→Market Outperform

HC Wainwright & Co.2026-03-31

Maintains

Buy→Buy

Goldman Sachs2026-03-31

Maintains

Neutral→Neutral

Wells Fargo2026-03-31

Maintains

Equal Weight→Equal Weight

Wedbush2026-01-13

Maintains

Outperform→Outperform

Wells Fargo2025-11-11

Maintains

Equal Weight→Equal Weight

HC Wainwright & Co.2025-08-22

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Bicara Therapeutics Inc. Common Stock (BCAX) stock. Of the recent 16 rating actions, 1 were upgrades and 0 were downgrades. 7 analysts currently cover BCAX.

分析师推荐趋势

Buy ratings1 → 1

Hold ratings1 → 1

Sell ratings0 → 0

BCAX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$0M

↓ 100.0% YoY

Revenue Next Year

$0M

EPS This Year

$-3.49

EPS Next Year

$-3.70

↑ 6.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BCAX EPS of $-3.49 for the current fiscal year, based on estimates from 11 analysts. The BCAX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

BCAX 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。BCAX 的共识目标价为 $28.60（+42.6% 上行空间），分析师共识为 Buy。

BCAX 的短期预测（明日）为 $19.48（-2.89%）。 BCAX 对 2027 年的股价预测均值为 $44。 BCAX 对 2030 年的预测区间为 $113–$127。

Bicara Therapeutics Inc. Common Stock 在 NASDAQ 上市，代码 BCAX。BCAX 在 2027 年的整体展望偏积极，在覆盖分析师中约 71% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

BCAX 预测 · 8 个问题

根据 7 位华尔街分析师，BCAX 的 12 个月平均目标价为 $28.60，最高 $42.00、最低 $18.00。若有图表，中位目标价可在上方查看。相对当前价 $20.05，隐含约 +42.6% 的上行空间。

BCAX 目标价BCAX 分析师目标价BCAX 12个月目标价目标价 BCAX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.